Literature DB >> 22579163

Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States.

Bruno Etain1, Mohamed Lajnef, Frank Bellivier, Flavie Mathieu, Aurélie Raust, Barbara Cochet, Sébastien Gard, Katia M'Bailara, Jean-Pierre Kahn, Orly Elgrabli, Renaud Cohen, Stéphane Jamain, Eduard Vieta, Marion Leboyer, Chantal Henry.   

Abstract

BACKGROUND: The clinical presentation, course, and comorbidities of bipolar disorder type I are highly heterogeneous, and this variability remains poorly predictable. Certain onset characteristics (eg, age and polarity at onset) may delineate subgroups differing in clinical expression and outcome.
METHOD: We retrospectively investigated the association between both age and polarity at onset and the clinical characteristics of bipolar I disorder (DSM-IV) in 2 independent adult samples: 480 French patients assessed in 1992-2006 (patients had been recruited from 3 university-affiliated psychiatry departments) and 714 US patients assessed in 1991-2003 (data were extracted from the Bipolar Disorder Phenome Database).
RESULTS: Polarity at onset correlated with subsequent predominance (P < .001). Most patients experienced a depressive onset (57.9% in France vs 71.0% in the United States; P < .001) associated with a higher density of depressive episodes, suicidal behavior, and alcohol misuse. A manic onset was associated with a higher density of manic episodes. Early onset was frequent in both countries (42% in France vs 68% in the United States; P < .001) and was associated with suicidal behavior and cannabis and cocaine/opiate misuse. Sensitivity for the prediction of clinical characteristics was 1%-35% for age at onset and 26%-47% for polarity at onset.
CONCLUSIONS: Onset characteristics are associated with subsequent predominant polarity, suicidal behavior, and substance misuse in bipolar I disorder. These findings may facilitate personalized treatment strategies based on type of onset and may also facilitate early focused strategies for preventing comorbidity. Given the relatively low sensitivity and specificity of these onset characteristics for predicting clinical variables, the relevance of age and polarity at onset as specifiers in nosographical classifications will require further studies. However, polarity at onset may be the more relevant specifier, with further investigation required for age at onset. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22579163     DOI: 10.4088/JCP.10m06504

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  Illness progression as a function of independent and accumulating poor prognosis factors in outpatients with bipolar disorder in the United States.

Authors:  Robert M Post; Lori L Altshuler; Gabriele S Leverich; Willem A Nolen; Ralph Kupka; Heinz Grunze; Mark A Frye; Trisha Suppes; Susan L McElroy; Paul E Keck; Mike Rowe
Journal:  Prim Care Companion CNS Disord       Date:  2014-12-18

2.  The Kindling/Sensitization Model and Early Life Stress.

Authors:  Robert M Post
Journal:  Curr Top Behav Neurosci       Date:  2021

3.  The Lausanne-Geneva cohort study of offspring of parents with mood disorders: methodology, findings, current sample characteristics, and perspectives.

Authors:  Caroline L Vandeleur; Marie-Pierre F Strippoli; Enrique Castelao; Mehdi Gholam-Rezaee; François Ferrero; Pierre Marquet; Jean-Michel Aubry; Martin Preisig
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-04-10       Impact factor: 4.328

4.  Anterior cingulate cortex choline levels in female adolescents with unipolar versus bipolar depression: a potential new tool for diagnosis.

Authors:  Xian-Feng Shi; Lauren N Forrest; M Danielle Kuykendall; Andrew P Prescot; Young-Hoon Sung; Rebekah S Huber; Tracy L Hellem; Eun-Kee Jeong; Perry F Renshaw; Douglas G Kondo
Journal:  J Affect Disord       Date:  2014-06-02       Impact factor: 4.839

Review 5.  Cannabis and development of dual diagnoses: A literature review.

Authors:  Rebecca C Hanna; Jessica M Perez; Subroto Ghose
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-09       Impact factor: 3.829

6.  Combined effect of TLR2 gene polymorphism and early life stress on the age at onset of bipolar disorders.

Authors:  José Oliveira; Bruno Etain; Mohamed Lajnef; Nora Hamdani; Meriem Bennabi; Djaouida Bengoufa; Aparna Sundaresh; Arij Ben Chaabane; Frank Bellivier; Chantal Henry; Jean-Pierre Kahn; Dominique Charron; Rajagopal Krishnamoorthy; Marion Leboyer; Ryad Tamouza
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 7.  The Use of Cannabis as a Predictor of Early Onset of Bipolar Disorder and Suicide Attempts.

Authors:  Rafaela Torres Portugal Leite; Sarah de Oliveira Nogueira; João Paulo Rodrigues do Nascimento; Laisa Soares de Lima; Taís Bastos da Nóbrega; Mariana da Silva Virgínio; Lucas Monte da Costa Moreno; Bruno Henrique Barbosa Sampaio; Fábio Gomes de Matos E Souza
Journal:  Neural Plast       Date:  2015-05-13       Impact factor: 3.599

8.  Clinical characteristics of bipolar disorder: a comparative study between Argentina and the United States.

Authors:  Jessica N Holtzman; Maria Lolich; Terence A Ketter; Gustavo H Vázquez
Journal:  Int J Bipolar Disord       Date:  2015-04-24

9.  Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder.

Authors:  Levi Roestad Kvitland; Ingrid Melle; Sofie Ragnhild Aminoff; Christine Demmo; Trine Vik Lagerberg; Ole Andreas Andreassen; Petter Andreas Ringen
Journal:  BMC Psychiatry       Date:  2015-02-05       Impact factor: 3.630

10.  Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study.

Authors:  Rashmi Patel; Peter Reiss; Hitesh Shetty; Matthew Broadbent; Robert Stewart; Philip McGuire; Matthew Taylor
Journal:  BMJ Open       Date:  2015-12-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.